About Xilis
Xilis is a company based in Durham (United States) founded in 2019 by Hans Clevers. Xilis has raised $116.26 million across 6 funding rounds from investors including ARE, Duke University and EQT. The company has 55 employees as of December 31, 2021. Xilis operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Durham, United States
- Employees 55 as on 31 Dec, 2021
- Founders Hans Clevers
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Xilis Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$116.26 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
ARE
& 13 more
-
Employee Count
55
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Xilis
Xilis has successfully raised a total of $116.26M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Xilis
Xilis has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Duke University and EQT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Seed & early stage VC firm investing the US
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for Xilis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xilis
Investment portfolio details for Xilis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xilis
Detailed financials for Xilis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xilis Comparisons
Peer comparison for Xilis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xilis
Xilis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Detailed competitors of Xilis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xilis
Complete news archive for Xilis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xilis
Xilis was founded in 2019.
Xilis is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Xilis is a funded company, having raised a total of $116.26M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Xilis is 55.
Xilis was founded in 2019 and is based in Durham, United States. A platform for drug discovery and precision therapy in oncology is provided by the company. Micro-organ sphere technologies are employed to support rapid diagnostics, personalized drug screening, and scalable patient-derived models. These capabilities are applied in immuno-oncology drug discovery, focusing on oncology sector operations.
Xilis's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
Xilis has 14 investors. Key investors include ARE, Duke University, EQT, Mubadala, and Pear VC.